A phase I clinical trial on intratumoral (IT) administration of ipilimumab (IPI) plus nivolumab (NIVO) followed by intracavitary (IC) administration of nivolumab in patients with recurrent glioblastoma

Activity: Talk or presentationTalk or presentation at a conference

Period2020 → …
Event titleESMO Immuno-Oncology Virtual Congres
Event typeConference